HomePress-release

Redding, California - July 28, 2022

Cell Culture Media Market Worth $14.64 billion by 2029

Cell Culture Media Market by Product (Serum-free, Chemically Defined, Classical, Xeno-free/Animal Component Free), Application (Monoclonal Antibody, Diagnostics, Cancer and Stem Cell Research), End User (Pharma & Biotech, Academic)- Global Forecast to 2029

Meticulous Research^®– leading market research company published a research report titled “Cell Culture Media Market by Product (Serum-free, Chemically Defined, Classical, Xeno-free/Animal Component Free), Application (Monoclonal Antibody, Diagnostics, Cancer and Stem Cell Research), End User (Pharma & Biotech, Academic)- Forecast to 2029”.

According to this latest publication from Meticulous Research®, the cell culture media market is expected to grow at a CAGR of 13.2% from 2022-2029 to reach $14.64 billion by 2029. The growing demand for monoclonal bodies, increasing prevalence of chronic diseases, rising funding for cell-based research, growing demand for biopharmaceuticals, and increase in R&D spending in the life science sector are primarily driving the growth of the cell culture media market.

Additionally, the growing adoption of 3D cell culture, the growth potential of personalized medicine, and emerging economies are expected to offer significant growth opportunities for players operating in the cell culture market in the coming years.

COVID-19 Pandemic Impact: Cell Culture Media Market

The COVID-19 pandemic raised worldwide awareness of the crucial role of scientific research in global health security. The most common cell cultures used during the pandemic were immortalized cell lines, such as HeLa, CHO, and Vero cells. Cell culture has been an invaluable tool for discovering the role of the human angiotensin-converting enzyme 2 (hACE2) cell surface receptor in facilitating viral entry into human cells. Cell cultures facilitated studies investigating the biology of SARS-CoV-2 infection and were harnessed for drug screening. They are also useful as a means for producing viral particles and therapeutics. Cell cultures have been an invaluable tool for biological studies and were a key contributor to the fight against COVID-19.

Governments and funding agencies allocated substantial resources to fund COVID-19-related research proposals and implemented funding rounds. Funding kept the pace of the research activities stable and helped in a detailed understanding of the pandemic's effects on human health.

As of May 2021, U.S. and Germany were the largest COVID-19 vaccine R&D investors, where the amount invested was USD 2 billion and USD 1.5 billion, respectively. Private companies received most of the funding, with more than USD 900 million received by Moderna, Inc. (U.S.) and Janssen Pharmaceuticals (Belgium) and USD 800 million by Pfizer Inc. (U.S.) and BioNTech SE (Germany).
In September 2021, the Australian Government provided USD 5 million to Walter and Eliza Hall Institute of Medical Research (Melbourne) to find a new, effective, safe antibody treatment to combat COVID-19. This includes diagnostics, vaccine development, antiviral development, clinical trials, digital health research infrastructure, and human immune response to COVID-19 infection.
In 2021, the National Institutes of Health (NIH) received USD 4.9 billion to fund important COVID-19 research on diagnostic tests, vaccines, and treatments.
As of August 2020, the Government of Canada funded grants to 140 COVID-19 research projects, and the total investment reached USD 111.1 million.
In 2020, CureVac N.V. (Germany) received initial funding of USD 8.3 million from Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate vaccine development against coronavirus.
In 2020, Harvard University (U.S.) and Guangzhou Institute for Respiratory Health (China) partnered to discover COVID-19 therapies. The two institutes received funding of USD 115 million from the China Evergrande Group to support research on the development of diagnostic tests, vaccines, and antiviral drugs.

As the funding supported the research studies, there was a rise in the adoption of cell culture media during the pandemic. The cell culture technique was useful for studying various coronavirus factors and antibody and vaccine production. Hence, COVID-19 had a positive impact on the cell culture media market.

The cell culture media market study presents historical market data in terms of values (2020 and 2021), estimated current data (2022), and forecasts for 2029. The cell culture market study includes the market analysis by product (serum-free media, chemically defined media, classical media, xeno-free/animal component free, other cell culture media), application [bioproduction (monoclonal antibody production, therapeutic protein production, vaccine production, and cell & gene therapy)], diagnostics, cancer research, drug screening & development, and stem cell research), end user (pharmaceutical & biotechnology companies, academic & research institutes, and diagnostic laboratories), and geography. The study also evaluates industry competitors and analyzes the regional and country markets.

Based on product, the cell culture media market is segmented into serum-free media, chemically defined media, classical media, animal component-free media, and other cell culture media. In 2022, the serum-free media segment is estimated to command the largest share of the cell culture media market. The major factor contributing to the large market share of this segment is the advantages of serum-free media over other media, such as the reduced risk of contamination and reproducibility of cell culture results.

Based on application, the cell culture media market is segmented into bioproduction, diagnostics, cancer research, drug screening and development, and stem cell research. The bioproduction segment is estimated to command the largest share of the cell culture media market in 2022. The major factors contributing to the large market share of this segment are growing research for novel products such as therapeutic proteins, vaccines, and cell & gene therapy products; government support for these research activities; and corporate funding for biotechnology-based start-ups.

Based on end user, the cell culture media market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and diagnostic laboratories. In 2022, the pharmaceutical & biotechnology companies segment is estimated to account for the largest share of the cell culture media market, primarily due to the rising need to boost cell culture performance in the manufacturing of therapeutic proteins like monoclonal antibodies, as well as in the production of viral vectors such as the adeno associated viral (AAV) vectors for gene therapy.

Geographic Review:

This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, and RoAPAC), Latin America, and the Middle East & Africa.

In 2022, North America is estimated to dominate the cell culture media market, followed by Europe and Asia-Pacific. Some of the major factors driving the growth of this regional segment include the increasing number of regulatory approvals for cell-based vaccines, growing focus on pharmaceutical & biopharmaceutical research, on-going capacity expansion by biopharmaceutical manufacturers, growing cell-based research funding, and the presence of major players.

Key Players:

The key players operating in the cell culture media market are Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), PromoCell GmbH (Germany), Cytiva (U.S.), Lonza Group Ltd (Switzerland), Corning Incorporated (U.S.), Becton, Dickinson and Company (U.S.), HiMedia Laboratories (India), Sartorius AG (Germany), FUJIFILM Holdings Corporation (Japan), Agilent Technologies, Inc. (U.S.), Miltenyi Biotec B.V. & Co. KG (Germany), BioLogos (U.S.), STEMCELL Technologies Inc. (Canada), and Cell Applications, Inc. (U.S.).

Download Report Sample - https://www.meticulousresearch.com/download-sample-report/cp_id=5318

Key questions answered in the report-

Which are the high-growth market segments in terms of product, application, end user, and region/country?
What was the historical market for cell culture media across the globe?
What are the market forecasts and estimates for the period 2022–2029?
What are the major drivers, restraints, opportunities, and challenges in the cell culture media market?
Who are the major players in the cell culture media market?
What is the competitive landscape, and who are the market leaders in the cell culture media market?
What are the recent developments in the cell culture media market?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

3D Printing

5G Technology

Advanced Chemical & Materials

Agrochemicals

Algae Products

Alternative Proteins

Animal Health

Artificial Intelligence

Automotive Technologies

Big Data Analytics

Climate Technologies

Edible Insects

Electric Vehicle

Food & Agriculture Technologies

Hydrogen Technologies

Internet Of Things

In Vitro Diagnostics

Laboratory Instrumentation

Language Learning Technologies

Medical Technologies

Next Generation Technologies

Processing & Packaging Technologies

Robotics & Automation

Smart Technologies

Water & Wastewater Technologies

Miscellaneous / Others

Redding, California - July 28, 2022

Cell Culture Media Market Worth $14.64 billion by 2029

Cell Culture Media Market by Product (Serum-free, Chemically Defined, Classical, Xeno-free/Animal Component Free), Application (Monoclonal Antibody, Diagnostics, Cancer and Stem Cell Research), End User (Pharma & Biotech, Academic)- Global Forecast to 2029

Recommended Readings

Advanced Chemical &
Materials

Food & Agriculture
Technologies

Next Generation
Technologies

Processing & Packaging
Technologies

Water & Wastewater
Technologies